Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,165 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Survival Outcomes of Patients with Primary Plasma Cell Leukemia in the Era of Proteasome Inhibitors and Immunomodulatory Agents: A Real-Life Multicenter Analysis.
Ataş Ü, Salim O, Iltar U, Yücel OK, Küçükdiler Eroğlu AH, Aslan V, Yıldırım M, Dedeoğlu Ö, Seçilmiş S, Ulaş T, Deveci B, Karaman Gulsaran S, Gedük A, Yaman F, Pınar İE, Maral S, Sarıcı A, Çelik S, Oğul H, Gülkan Özkan S, Gemici A, Güneş AK, Tombak A, Yavaşoğlu İ, Karakuş V, Cömert M, Toptaş T, Dal MS, Saba R, Kırkızlar HO, Mehtap Ö, Gündüz E, Özkalemkaş F, Albayrak M, Berber İ, Keklik M, Güler N, Özkan HA, Sevindik ÖG, Bolaman Z, Kurtoğlu E, Aylı M, Fıratlı Tuğlular T, Altuntaş F, Ündar L. Ataş Ü, et al. Among authors: celik s. Turk J Haematol. 2024 Dec 2;41(4):225-235. doi: 10.4274/tjh.galenos.2024.2023.0450. Epub 2024 Nov 6. Turk J Haematol. 2024. PMID: 39501735 Free PMC article.
Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies.
Civriz Bozdağ S, Cengiz Seval G, Yönal Hindilerden İ, Hindilerden F, Andıç N, Baydar M, Aydın Kaynar L, Toprak SK, Göksoy HS, Balık Aydın B, Demirci U, Can F, Özkocaman V, Gündüz E, Güven ZT, Özkurt ZN, Demircioğlu S, Beksaç M, İnce İ, Yılmaz U, Eroğlu Küçükdiler H, Abishov E, Yavuz B, Ataş Ü, Mutlu YG, Baş V, Özkalemkaş F, Üsküdar Teke H, Gürsoy V, Çelik S, Çiftçiler R, Yağcı M, Topçuoğlu P, Çeneli Ö, Abbasov H, Selim C, Ar MC, Yücel OK, Sadri S, Albayrak C, Demir AM, Güler N, Keklik M, Terzi H, Doğan A, Yegin ZA, Kurt Yüksel M, Sadri S, Yavaşoğlu İ, Beköz HS, Aksu T, Maral S, Erol V, Kaynar L, İlhan O, Bolaman AZ, Sevindik ÖG, Akyay A, Özcan M, Gürman G, Ünal Ş, Yavuz Y, Diz Küçükkaya R, Özsan GH. Civriz Bozdağ S, et al. Among authors: celik s. Turk J Haematol. 2022 Feb 23;39(1):43-54. doi: 10.4274/tjh.galenos.2021.2021.0287. Epub 2021 Sep 15. Turk J Haematol. 2022. PMID: 34521187 Free PMC article.
The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL.
Akpinar S, Dogu MH, Celik S, Ekinci O, Hindilerden IY, Dal MS, Davulcu EA, Tekinalp A, Hindilerden F, Ozcan BG, Hacibekiroglu T, Erkurt MA, Bagci M, Namdaroglu S, Korkmaz G, Bilgir O, Cagliyan GA, Ozturk HBA, Serin I, Tiryaki TO, Ozatli D, Korkmaz S, Ulas T, Eser B, Turgut B, Altuntas F. Akpinar S, et al. Among authors: celik s. Clin Lymphoma Myeloma Leuk. 2022 Mar;22(3):169-173. doi: 10.1016/j.clml.2021.09.010. Epub 2021 Sep 15. Clin Lymphoma Myeloma Leuk. 2022. PMID: 34629286
Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey.
Dal MS, Ulu BU, Uzay A, Akay OM, Beşışık S, Yenerel MN, Çelik S, Kaynar L, Yücel OK, Deveci B, Sönmez M, Mehtap Ö, Beköz HS, Sunu C, Salim O, Ulaş T, Kartı S, Altuntaş F, Ferhanoğlu B, Tuğlular TF. Dal MS, et al. Among authors: celik s. Ann Hematol. 2023 Jan;102(1):133-140. doi: 10.1007/s00277-022-05052-x. Epub 2022 Nov 19. Ann Hematol. 2023. PMID: 36401621 Free PMC article.
1,165 results